TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
WALTHAM, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25, 2025 at 10:00 a.m. Eastern Time.
A webcast of the fireside chat will be available on the 'Events and Presentations' section of the Company's website at ir.tscan.com. An archived replay of the webcast will be available on the Company's website for 90 days following the event.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA™ Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company's repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers (the PLEXI-TTM Phase 1 solid tumor trial). The Company is currently enrolling patients into both clinical programs.
Contacts
Heather SavelleTScan Therapeutics, Inc.VP, Investor Relations857-399-9840hsavelle@tscan.com
Maghan MeyersArgot Partners212-600-1902TScan@argotpartners.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Why Rocket Lab Stock Skyrocketed This Week
The S&P 500 index hit a new record high this week, and so did Rocket Lab stock. Rocket Lab announced that it had entered into a contract to provide two satellite launches for the European Space Agency. The company also launched two of its Electron rockets this week and marked its fastest-ever consecutive launches. 10 stocks we like better than Rocket Lab › Rocket Lab (NASDAQ: RKLB) stock soared this week thanks to a combination of bullish catalysts. The space-tech company's share price climbed 17.8% from the previous Friday's market close in a stretch that saw the S&P 500 index rise 3.4% and set a new record high. Strong bullish momentum shaped the broader market this week as the new ceasefire between Israel and Iran lessened geopolitical volatility and investors bet that the Federal Reserve is poised to take a more dovish stance on interest rates. Rocket Lab stock also got a boost from new rocket launches and rising excitement surrounding defense applications within the space industry. In addition to the bullish backdrop for the broader market, some major business-specific news pushed Rocket Lab's valuation higher this week. As with the S&P 500, the company's stock hit a new record in this week's trading. Rocket Lab announced on Wednesday that it won a new contract with the European Space Agency (ESA) for two satellite launches. The first of the launches could take place as early as December, and the ESA said that it had selected Rocket Lab for the missions because rapid turnaround time for the initiatives was a key priority. Rocket Lab published a press release on Thursday announcing that it had successfully completed the launch of its 67th Electron rocket, which carried four satellites into low-Earth orbit for HawkEye 360 -- a provider of geospatial analytics. The company followed it up with the 68th successful Electron launch on Saturday, marking its fastest-ever turnaround between launches. The space-tech specialist now has a market capitalization of roughly $16.3 billion and is valued at approximately 28.5 times this year's expected sales. While the company's growth-dependent valuation creates potential for downside volatility, the business does appear to be scoring some big wins and is scaling rapidly. Before you buy stock in Rocket Lab, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Rocket Lab wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Rocket Lab. The Motley Fool has a disclosure policy. Why Rocket Lab Stock Skyrocketed This Week was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
ELV截止日期：Rosen Law Firm敦促損失超過10萬美元的Elevance Health, Inc. (NYSE: ELV)股東與法律事務所聯絡以瞭解有關其權利的資訊
紐約--(BUSINESS WIRE)--(美國商業資訊)-- 全球投資人權益法律事務所Rosen Law Firm提醒投資人，一名股東代表在2024年4月18日至2024年10月16日期間購買Elevance Health, Inc. (NYSE: ELV)普通股的投資人提起了集體訴訟。Elevance將自身描述為「一家為多個市場提供健康保險計畫的醫療保健公司」。 如欲瞭解更多資訊，請遞交 表格 、向Phillip Kim律師 寄送電子郵件 ，或致電866-767-3653聯絡我們。 指控內容：Rosen Law Firm正在調查對Elevance Health, Inc. (NYSE: ELV)在其業務營運方面誤導投資人的指控。 起訴書指稱，被告做出了虛假和/或誤導性陳述及/或未揭露：在醫療補助(Medicaid)重新認定程序接近完成時，被告向投資人表示，其正密切監控與重新認定程序相關的成本趨勢，且Elevance與各州協商的保費費率足以因應繼續參加醫療補助計畫病患的風險和成本狀況。儘管被告承認醫療補助支出在上升，但仍多次向投資人保證，這已充分反映在Elevance的年度指引中。這些陳述存在重大虛假或誤導性。事實上，重新認定導致Elevance醫療補助會員的疾病嚴重程度和醫療服務利用率顯著上升，因為被移出醫療補助計畫的會員平均而言比保留資格的會員更健康。這一變化的程度並未反映在Elevance與各州的費率協商中，也未體現在其2024年的財務指引裡。訴訟稱，當市場瞭解真實詳情後，投資人蒙受了損失。 現在怎麼辦：您可能有資格參與針對Elevance Health, Inc.的集體訴訟。如果有股東希望擔任該集體訴訟的原告代表，則必須在2025年7月11日之前向法院提出申請。原告代表是指代表其他集體訴訟成員主導訴訟的當事人代表。您無需參與此案即有資格獲得追償。如果您選擇不採取任何行動，您也可以保持缺席集體訴訟成員的身分。如欲瞭解更多資訊，請點選 此處 。 所有代理均為勝訴後取酬。股東無需支付任何費用或開支。 關於Rosen Law Firm：與Rosen Law Firm不同，一些就此等事宜發表公告的法律事務所並不會實際提起證券集體訴訟。身為股東權益訴訟領域公認的領導者， Rosen Law Firm 一直致力於協助股東挽回損失、改善公司治理結構，並追究公司高階主管的違法行為責任。自成立以來，Rosen Law Firm已經為股東挽回了超過10億美元的損失。 請在LinkedIn： 、Twitter： 或Facebook： 上關注我們，以瞭解最新情況。 律師廣告。先前案例不保證可獲致類似結果。 免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯一具法律效力之版本。
Business Insider
an hour ago
- Business Insider
Rubrik, Inc. Class A (RBRK) Receives a Buy from Citi
In a report released on June 27, Fatima Boolani from Citi maintained a Buy rating on Rubrik, Inc. Class A (RBRK – Research Report), with a price target of $117.00. The company's shares closed last Friday at $87.38. Don't Miss TipRanks' Half Year Sale Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Boolani covers the Technology sector, focusing on stocks such as Cloudflare, Check Point, and Fortinet. According to TipRanks, Boolani has an average return of 21.1% and a 66.38% success rate on recommended stocks. Rubrik, Inc. Class A has an analyst consensus of Strong Buy, with a price target consensus of $111.06, which is a 27.10% upside from current levels. In a report released on June 25, Robert W. Baird also maintained a Buy rating on the stock with a $110.00 price target. RBRK market cap is currently $16.91B and has a P/E ratio of -30.76. Based on the recent corporate insider activity of 118 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RBRK in relation to earlier this year. Earlier this month, Enrique Salem, a Director at RBRK sold 700,000.00 shares for a total of $63,763,000.00.
